Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production

• Published in: Diabetes (New York, N.Y.) Vol. 64; no. 3; pp. 819 - 827
• Main Authors: Jun, Lucy S, Millican, Rohn L, Hawkins, Eric D, Konkol, Debra L, Showalter, Aaron D, Christe, Michael E, Michael, M Dodson, Sloop, Kyle W
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01-03-2015
• Subjects: Animals; Cells; Diabetes; Glucagon - metabolism; Glucagon-Like Peptide 1 - metabolism; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose - metabolism; Homeostasis; Immunohistochemistry; Insulin; Insulin - metabolism; Mice; Mice, Knockout; Receptors, Glucagon - antagonists & inhibitors; Receptors, Glucagon - deficiency; Receptors, Glucagon - genetics; Receptors, Glucagon - metabolism; Rodents; Streptozocin - pharmacology
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db14-1052

The absence of insulin results in oscillating hyperglycemia and ketoacidosis in type 1 diabetes. Remarkably, mice genetically deficient in the glucagon receptor (Gcgr) are refractory to the pathophysiological symptoms of insulin deficiency, and therefore, studies interrogating this unique model may uncover metabolic regulatory mechanisms that are independent of insulin. A significant feature of Gcgr-null mice is the high circulating concentrations of GLP-1. Hence, the objective of this report was to investigate potential noninsulinotropic roles of GLP-1 in mice where GCGR signaling is inactivated. For these studies, pancreatic β-cells were chemically destroyed by streptozotocin (STZ) in Gcgr(-/-):Glp-1r(-/-) mice and in Glp-1r(-/-) animals that were subsequently treated with a high-affinity GCGR antagonist antibody that recapitulates the physiological state of Gcgr ablation. Loss of GLP-1 action substantially worsened nonfasting glucose concentrations and glucose tolerance in mice deficient in, and undergoing pharmacological inhibition of, the GCGR. Further, lack of the Glp-1r in STZ-treated Gcgr(-/-) mice elevated rates of endogenous glucose production, likely accounting for the differences in glucose homeostasis. These results support the emerging hypothesis that non-β-cell actions of GLP-1 analogs may improve metabolic control in patients with insulinopenic diabetes.